{"nctId":"NCT01038427","briefTitle":"A Study Comparing the Clinical Equivalence of Two Mometasone Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis","startDateStruct":{"date":"2009-12-02","type":"ACTUAL"},"conditions":["Rhinitis, Allergic, Seasonal"],"count":795,"armGroups":[{"label":"Test","type":"EXPERIMENTAL","interventionNames":["Drug: Mometasone furoate 50 mcg/actuation nasal spray (Lek Pharmaceuticals)"]},{"label":"Reference","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Mometasone furoate (Nasonex®) 50 mcg/actuation nasal spray"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Mometasone furoate 50 mcg/actuation nasal spray (Lek Pharmaceuticals)","otherNames":[]},{"name":"Mometasone furoate (Nasonex®) 50 mcg/actuation nasal spray","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or non-pregnant, non-lactating female 12 years of age or older with a minimum of 2 years of previous history of seasonal allergic rhinitis to the pollen/allergen in season at the time the study is being conducted.\n* Signed informed consent form. For patients under the age of majority the parent or legal guardian should sign the consent form and the child will be required to sign a patient \"assent\" form.\n* Documented positive allergic skin test to local pollen, performed within the past 12 months.\n* A score of at least 6 on the reflective Total Nasal Symptom Score (rTNSS) with a minimum score of at least 2 for \"nasal congestion\" and a minimum score of at least 2 for one of the remaining 3 symptoms.\n\nExclusion Criteria:\n\n* Females who are pregnant, lactating or likely to become pregnant during the study.\n* History of asthma over the previous two years that required chronic therapy (with the exception of occasional acute or mild exercise induced asthma).\n* Patients with some nasal conditions, or with clinically significant nasal deformity or any recent nasal surgery or trauma that has not completely healed.\n* Upper respiratory tract infection or any untreated infections within the previous 30 days.\n* Patient has started immunotherapy/changed the dose within 30 days of starting the study or has desensitization therapy to the seasonal allergen that is causing the allergic rhinitis within the previous 6 months.\n* Patients with a history of tuberculosis, or with the presence of glaucoma, cataracts, ocular herpes simplex, conjunctivitis or other eye infection not related to the diagnosis of seasonal allergic rhinitis within 14 days of enrollment.\n* The patient has had recent exposure (30 days) or was at risk of being exposed to chicken pox or measles.\n* Any known hypersensitivity to mometasone, other steroids or any of the components of the study nasal spray.\n* Planned travel outside of the local area for more than 2 consecutive days or 3 days in total.\n* The patient has a history of alcohol or drug abuse.","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Change From Baseline in Reflective Total Nasal Symptom Score (rTNSS) (Equivalence: Per-Protocol Population)","description":"Patients were required to record a 12 hour \"reflective\" score twice a day approximately 12 hours apart. For the rTNSS patients were asked to \"look back\" or \"reflect\" on their severity of nasal symptoms over the previous 12 hours. The first rating on each day was taken prior to dosing. Patients were asked to score 4 nasal symptoms (nasal congestion, runny nose, sneezing and itchy nose) on a 4 point scale ranging from 0 (no symptom) to 3 (severe symptom). The means of the 4 individual symptom scores obtained over the randomized treatment period were summed to give the mean rTNSS, which ranged from 0 to 12 with a lower score indicating less severe symptoms.\n\nMean baseline rTNSS was calculated by summing the means of the 4 individual symptom scores obtained over the 72 hours before the randomized treatment period.\n\nMean change from baseline was calculated as \"mean baseline rTNSS\" - \"mean post-randomization rTNSS\". A positive change from baseline in rTNSS is considered a favorable outcome.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.981","spread":"2.335"},{"groupId":"OG001","value":"1.817","spread":"2.258"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline in Reflective Total Nasal Symptom Score (rTNSS) (Superiority: Intent-to-Treat Population)","description":"Patients were required to record a 12 hour \"reflective\" score twice a day approximately 12 hours apart. For the rTNSS patients were asked to \"look back\" or \"reflect\" on their severity of nasal symptoms over the previous 12 hours. The first rating on each day was taken prior to dosing. Patients were asked to score 4 nasal symptoms (nasal congestion, runny nose, sneezing and itchy nose) on a 4 point scale ranging from 0 (no symptom) to 3 (severe symptom). The means of the 4 individual symptom scores obtained over the randomized treatment period were summed to give the mean rTNSS, which ranged from 0 to 12 with a lower score indicating less severe symptoms.\n\nMean baseline rTNSS was calculated by summing the means of the 4 individual symptom scores obtained over the 72 hours before the randomized treatment period.\n\nMean change from baseline was calculated as \"mean baseline rTNSS\" - \"mean post-randomization rTNSS\". A positive change from baseline in rTNSS is considered a favorable outcome.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.008","spread":"2.356"},{"groupId":"OG001","value":"1.794","spread":"2.257"},{"groupId":"OG002","value":"1.034","spread":"1.894"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Instantaneous Total Nasal Symptom Score (iTNSS) (Equivalence: Per-Protocol Population)","description":"Patients were required to record an \"instantaneous\" score twice a day approximately 12 hours apart. For the iTNSS patients were asked to evaluate \"how I feel now\" regarding their severity of nasal symptoms. The first rating on each day was taken prior to dosing. Patients were asked to score 4 nasal symptoms (nasal congestion, runny nose, sneezing and itchy nose) on a 4 point scale ranging from 0 (no symptom) to 3 (severe symptom). The means of the 4 individual symptom scores obtained over the randomized treatment period were summed to give the mean iTNSS, which ranged from 0 to 12 with a lower score indicating less severe symptoms.\n\nMean baseline iTNSS was calculated by summing the means of the 4 individual symptom scores obtained over the 72 hours before the randomized treatment period.\n\nMean change from baseline was calculated as \"mean baseline iTNSS\" - \"mean post-randomization iTNSS\". A positive change from baseline in iTNSS is considered a favorable outcome.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.900","spread":"2.408"},{"groupId":"OG001","value":"1.656","spread":"2.207"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Instantaneous Total Nasal Symptom Score (iTNSS) (Superiority: Intent-to-Treat Population)","description":"Patients were required to record an \"instantaneous\" score twice a day approximately 12 hours apart. For the iTNSS patients were asked to evaluate \"how I feel now\" regarding their severity of nasal symptoms. The first rating on each day was taken prior to dosing. Patients were asked to score 4 nasal symptoms (nasal congestion, runny nose, sneezing and itchy nose) on a 4 point scale ranging from 0 (no symptom) to 3 (severe symptom). The means of the 4 individual symptom scores obtained over the randomized treatment period were summed to give the mean iTNSS, which ranged from 0 to 12 with a lower score indicating less severe symptoms.\n\nMean baseline iTNSS was calculated by summing the means of the 4 individual symptom scores obtained over the 72 hours before the randomized treatment period.\n\nMean change from baseline was calculated as \"mean baseline iTNSS\" - \"mean post-randomization iTNSS\". A positive change from baseline in iTNSS is considered a favorable outcome.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.932","spread":"2.419"},{"groupId":"OG001","value":"1.630","spread":"2.214"},{"groupId":"OG002","value":"0.905","spread":"1.914"}]}]}]},{"type":"SECONDARY","title":"Clinical Global Improvement Based on the Investigator's Assessment","description":"A global evaluation of efficacy relative to baseline was assessed separately by the investigator and the patient on Day 15. Both the investigator and the patient were asked to rate clinical improvement since baseline on a 5-category scale ranging from \"No Relief\" to \"Complete Relief\" of signs and symptoms of seasonal allergic rhinitis. This record shows the clinical global improvement based on the investigator's assessment.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"53","spread":null},{"groupId":"OG002","value":"39","spread":null}]},{"measurements":[{"groupId":"OG000","value":"83","spread":null},{"groupId":"OG001","value":"72","spread":null},{"groupId":"OG002","value":"38","spread":null}]},{"measurements":[{"groupId":"OG000","value":"125","spread":null},{"groupId":"OG001","value":"119","spread":null},{"groupId":"OG002","value":"56","spread":null}]},{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"67","spread":null},{"groupId":"OG002","value":"23","spread":null}]},{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Global Improvement Based on the Patient's Assessment","description":"A global evaluation of efficacy relative to baseline was assessed separately by the investigator and the patient on Day 15. Both the investigator and the patient were asked to rate clinical improvement since baseline on a 5-category scale ranging from \"No Relief\" to \"Complete Relief\" of signs and symptoms of seasonal allergic rhinitis. This record shows the clinical global improvement based on the patient's assessment.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"36","spread":null},{"groupId":"OG002","value":"27","spread":null}]},{"measurements":[{"groupId":"OG000","value":"83","spread":null},{"groupId":"OG001","value":"83","spread":null},{"groupId":"OG002","value":"46","spread":null}]},{"measurements":[{"groupId":"OG000","value":"115","spread":null},{"groupId":"OG001","value":"111","spread":null},{"groupId":"OG002","value":"58","spread":null}]},{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"73","spread":null},{"groupId":"OG002","value":"24","spread":null}]},{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":317},"commonTop":["Headache"]}}}